January 1, 2011 Journal article Open Access

Barak; Paola Ferrari; Angelo Carpi; Andrea Nicolini; Paolo Miccoli; Massimo Conte; Michael J. Duffy; Giorgio Rossi

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Barak</dc:creator>
  <dc:creator>Paola Ferrari</dc:creator>
  <dc:creator>Angelo Carpi</dc:creator>
  <dc:creator>Andrea Nicolini</dc:creator>
  <dc:creator>Paolo Miccoli</dc:creator>
  <dc:creator>Massimo Conte</dc:creator>
  <dc:creator>Michael J. Duffy</dc:creator>
  <dc:creator>Giorgio Rossi</dc:creator>
  <dc:date>2011-01-01</dc:date>
  <dc:description>Metastatic colorectal and other locally advanced gastrointestinal (G.I.) cancers often recur after curative resection. Many mechanisms of tumor growth and/or immune escape by residual cancer cells may provoke tumor progression. Long-term, cytostatic action with repeated post-adjuvant administration of 5-fluorouracil (FU)-leucovorin (LV) cycles may interrupt or downregulate these mechanisms and favor the recovery and/or increase the immune system activity. Seventy patients were considered. An active prospective cohort including 21 patients (study group) was matched in a 1:1 ratio with a retrospective parallel control group of 21 patients. The study group received long-term repeated post-adjuvant administration of 5-FU-LV cycles, while the matched control group was conventionally treated. Statistical analysis was performed by Kaplan-Meier method and Cox's proportional hazard regression model. The five-year disease-free survival (DFS) was 77.0 + 10.1 % and 31.7 + 10.6 % (p = 0.001; hazard ratio (HR) 5.3, 95 % C.I.: 1.7-16.1, p = 0.003), while the five-year overall survival (OS) was 88.0 + 8.1 % and 37.0 + 10.7 % (p = 0.001; HR 8.9, 95 % C.I.: 2.0-39.9, p = 0.004) in the study group and in matched controls respectively. These findings suggest a relevant improvement in the outcome of this population by an intermittent and prolonged cytostatic effect with 5-FU-LV.</dc:description>
  <dc:identifier>https://www.openaccessrepository.it/record/119229</dc:identifier>
  <dc:identifier>10.2741/e348</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>url:https://www.openaccessrepository.it/communities/itmirror</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:subject>General Immunology and Microbiology</dc:subject>
  <dc:subject>General Biochemistry, Genetics and Molecular Biology</dc:subject>
  <dc:title>Additional 5-FU-LV significantly increases survival in gastrointestinal cancer.</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>